Metformin에 추가로 병용되는 SGLT2 inhibitors의 효능과 안전성에 관한 고찰

키워드

참고문헌 (37)

1. "Korean statistical Information Service"[URL]
2. American Diabetes Association, "8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018", Diabetes Care, 41(Supplement 1), pp.S73~S85 (2018)[DOI]
3. "Canagliflozin prescribing information"[URL]
4. "Find medicine"[URL]
5. "Jardiance prescribing information"[URL]
6. "Ipragliflozin (Suglat) First of new diabetes drug class in Japan"[URL]
7. "Online medicine library"[URL]
8. Kawalec P, "The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis", Diabetes Metab Res Rev, 30(4), pp.269~283 (2014)[DOI]
9. "Health insurance review & assessment service"[URL]
10. Fujita Y, "Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action", J Diabetes Invest, 5, pp.265~275 (2014)[DOI]
11. Monica Reddy RP, "SGLT2 inhibitors in the management of type 2 diabetes", Endocrine, 53(2), pp.364~372 (2016)[DOI]
12. "Drugs@FDA, Farxiga prescribing information"[URL]
13. Kasichayanula S, "Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects", Diabetes Obes Metab, 13(8), pp.770~773 (2011)[DOI]
14. "Product information"[URL]
15. Nauck MA, "Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, doubleblind, active-controlled noninferiority trial", Diabetes Care, 34(9), pp.2015~2022 (2011)[DOI]
16. Nauck MA, "Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin", Diabetes Obes Metab, 16(11), pp.1111~1120 (2014)[DOI]
17. Del Prato S, "Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data", Diabetes Obes Metab, 17(6), pp.581~590 (2015)[DOI]
18. Bailey CJ, "Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial", BMC Med, 11, pp.43~ (2013)[DOI]
19. Bailey CJ, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial", Lancet, 375(9733), pp.2223~2233 (2010)[DOI]
20. Bolinder J, "Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin", Diabetes Obes Metab, 16(2), pp.159~169 (2014)[DOI]
21. Zhang Q, "Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses", Diabetes Res Clin Pract, 105(3), pp.313~321 (2014)[DOI]
22. Araki E, "Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus", Diabetes Obes Metab, 17(7), pp.665~674 (2015)[DOI]
23. Dziuba J, "Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes", Diabetes Obes Metab, 16(7), pp.628~635 (2014)[DOI]
24. Zinman B, "Empagliflozin, Cardiovascular outcomes, and mortality in type 2 Diabetes", N Engl J Med, 373(22), pp.2117~2128 (2015)[DOI]
25. Inzucchi SE, "SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials", Diab Vasc Dis Res, 12(2), pp.90~100 (2015)[DOI]
26. Abdul-Ghani M, "SGLT2 Inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME Study", Diabetes Care, 39(5), pp.717~725 (2016)[DOI]
27. Rizzo M, "Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives", Expert Opin Pharmacother, 16(3), pp.281~284 (2015)[DOI]
28. Monami M, "Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials", Diabetes Obes Metab, 16(5), pp.457~466 (2014)[DOI]
29. Lin HW, "A Review on the relationship between SGLT2 Inhibitors and cancer", Int J Endocrinol, 2014, pp.719578~ (2014)
30. Gallo LA, "Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences", Diab Vasc Dis Res, 12(2), pp.78~89 (2015)[DOI]
31. Ndefo UA, "Empagliflozin (Jardiance): A novel SGLT2 Inhibitor for the treatment of type-2 diabetes", Pharmacy and Therapeutics, 40(6), pp.64~68 (2015)
32. Veltkamp SA, "Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose cotransporter 2 inhibitor, on urinary glucose excretion in healthy subjects", Clin Drug Investig, 31(12), pp.839~851 (2011)[DOI]
33. "Glucophage prescribing information"[URL]
34. Rosenstock J, "Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia", Diabetes Obes Metab, 15(12), pp.1154~1160 (2013)[DOI]
35. Haring HU, "Empagliflozin as addon to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial", Diabetes Care, 37(6), pp.1650~1659 (2014)[DOI]
36. Wilding JP, "Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study", Diabetes Obes Metab, 15(5), pp.403~9 (2013)[DOI]
37. Kashiwagi A, "Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 dia- betes: ILLUMINATE, a randomized, double-blind, placebo-controlled study", Diabetes Obes Metab, 17(3), pp.304~308 (2015)[DOI]

관련 논문AI추천